The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis

BACKGROUND: The future of combined immunotherapy (a PD-1/PD-L1 plus a CTLA-4 antagonist) is very bright. However, besides improving efficacy, combined therapy increases treatment-related adverse events (TRAEs). Also, the clinical application is limited in some solid tumors. METHODS: This paper purpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Lihu, Khadaroo, Parikshit Asutosh, Su, Hui, Kong, Liya, Chen, Liangliang, Wang, Xianfa, Li, Xinlong, Zhu, Hepan, Zhong, Xin, Pan, Junhai, Chen, Manman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558837/
https://www.ncbi.nlm.nih.gov/pubmed/31182049
http://dx.doi.org/10.1186/s12885-019-5785-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558837/
https://www.ncbi.nlm.nih.gov/pubmed/31182049
http://dx.doi.org/10.1186/s12885-019-5785-z

Ejemplares similares